Governments, patient advocates, and life-science organizations across the globe are weighing the economic and privacy matters surrounding the commercialization of medical records. In this new op-ed, Datacubed Health CSO Paul Glimcher discusses the commercialization and ownership of medical records.
Datacubed Health’s Paul Glimcher and Jenn Cho discuss how geofencing technology can drastically reduce missing data in clinical trials.
Janssen has selected Datacubed Health to provide geofencing technology solutions in order to detect patient hospitalizations in clinical trials.
Datacubed Health today launches the Linkt Location app, which tracks participant interactions with health care facilities, providing reminders and other communications to garner insight into health events that are often unreported.
With virtual health transforming the entire healthcare landscape, pharma is leveraging digital health tools to improve its processes.
Today’s mostly paper-dependent clinical trials pose fundamental challenges to the pharmaceutical industry. Such trials can be prohibitively expensive, struggle to enroll and retain a sufficient number of participants, and have difficulty maintaining compliance and data reliability. But with the advent of virtual and partially virtual trials using digital tools and devices, we have the opportunity to substantially improve efficiency by deploying the same design principles that make consumer apps so successful.
How close are we to personalizing healthcare? This was the theme of MM&M and Deloitte Digital’s aptly named event, Humanizing the Health Experience, which took place at Deloitte Digital’s downtown NYC offices earlier this month.
Scientists with the Dominantly Inherited Alzheimer Network (DIAN) at the Washington University in St. Louis School of Medicine are undertaking five years of studies of a rare form of early-onset Alzheimer’s disease using a “bring your own device” (BYOD) study model.
The Washington University School of Medicine in Saint Louis has selected Datacubed Health’s mobile platform has been selected to support worldwide studies for those at risk of Dominantly Inherited Alzheimer’s Disease, a rare form of early-onset Alzheimer’s Disease. The Linkt platform enables the collection of real-time data on sleep, diet and other biomarkers using a “bring your own device” (BYOD) study model.
The Washington University School of Medicine in St. Louis is launching a five-year study that will use an mHealth app and connected health platform to monitor people living with Dominantly Inherited Alzheimer’s Disease.